Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.74 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.70 |
| ▸ | PDE2A | O00408 | 1/20 | 0.70 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.70 |
| ▸ | PDE6D | O43924 | 1/20 | 0.70 |
| ▸ | PDE8A | O60658 | 1/20 | 0.70 |
| ▸ | PDE9A | O76083 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | PDE6A | P16499 | 1/20 | 0.70 |
| ▸ | PDE6G | P18545 | 1/20 | 0.70 |
| ▸ | PDE4A | P27815 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | PDE6B | P35913 | 1/20 | 0.70 |
| ▸ | PDE6C | P51160 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23370687 | 0.96 | PDE5A (0.77) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL23370701 | 0.94 | PDE5A (0.73) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL23370656 | 0.92 | PDE5A (0.75) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL23370659 | 0.91 | PDE5A (0.73) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL23370686 | 0.90 | PDE5A (0.79) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL16972444 | 0.89 | PDE5A (0.82) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL23361694 | 0.89 | PDE5A (0.68) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL23361674 | 0.87 | PDE5A (0.78) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL29602364 | 0.87 | PDE5A (0.78) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL23370685 | 0.87 | PDE5A (0.80) | PDE5APDE3BPDE3AABCC4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058457-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS | Ildong Pharmaceutical Co., Ltd. (KR) | 2022-09-21 | — | — | EP | disclosed |
| US-20220153746-A1 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-19 | — | — | US | disclosed |
| US-20220153746-A1 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-19 | — | — | US | disclosed |
| WO-2022096930-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021094830-A2 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153746-A1 | NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF | PDE6G, PRKG1, PDE6D | PDE5A 4/4885PDE3B 12/4885PDE3A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.